Cetirizine

4 trials 3 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

3 Sponsors

4 Countries

Phase III

Phase II

Phase I

Phase III: 1 Phase II: 2 Phase I: 1

Indications tested

Relapsing multiple sclerosis 2 Myasthenia gravis 1

Sponsors using this IMP

Tg Therapeutics Inc. 2 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 Institut Jules Bordet 1

All trials

4 total

Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Phase III 1 country Tg Therapeutics Inc.
A Phase-2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Enc… Recruiting

2023-504686-23-00 Phase II 2 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Immunological variables associated to ICI toxicity in cancer patients Recruiting

2023-505360-11-00 Phase II 1 country Institut Jules Bordet
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended

2023-509555-13-00 Phase I 1 country Tg Therapeutics Inc.

Showing 1–4 of 4 trials

← All drugs A–Z